Blood | 2019
Venetoclax: R-CHOP rocket booster?
Abstract
In this issue of Blood , Zelenetz et al 1 report the results of the phase 1b portion of the CAVALLI study, one of the first trials to explore a novel strategy of chemosensitization, by adding the B-cell leukemia/lymphoma-2 (BCL2) inhibitor venetoclax to chemoimmunotherapy for patients with non-Hodgkin lymphoma (NHL).